Clinical Trial Update: Bevacizumab for Recurrent Malignant Glioma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating bevacizumab for recurrent malignant glioma reported results (posted in 2012).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-grade Glioma
• Malignant Glioma

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent High-Grade Gliomas, Malignant Gliomas | Phase 2 | Status: COMPLETED | Results posted: 2012-06-08